| 2024-02-22 | +56.8% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2024-11-07 | -38.0% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-08-12 | +32.1% | news | Seeking Alpha | Maravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026 |
| 2025-08-12 | +32.1% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2025 Earnings Call Transcript |
| 2025-08-12 | +32.1% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-12 | +32.1% | earnings | Yahoo Finance | Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance |
| 2023-11-07 | -31.6% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-02-24 | -22.7% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Q4 2024 Earnings Preview |
| 2025-08-11 | +21.4% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Non-GAAP EPS of -$0.08 misses by $0.01, revenue of $47.4M in-line |
| 2025-08-11 | +21.4% | legal | SEC EDGAR | MRVI 8-K: 2.02, 2.05, 5.02 (SEC Filing) |
| 2022-10-03 | -21.2% | legal | SEC EDGAR | MRVI 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-02-25 | -18.5% | earnings | Seeking Alpha | Maravai postpones earnings release, delays annual report |
| 2025-02-25 | -18.5% | legal | SEC EDGAR | MRVI 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-01-08 | -18.5% | legal | SEC EDGAR | MRVI 8-K: 2.02 and 5.02 (SEC Filing) |
| 2023-05-08 | -16.0% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2022-01-03 | -15.9% | legal | SEC EDGAR | MRVI 8-K: 8.01 and (SEC Filing) |
| 2022-10-19 | -15.6% | legal | SEC EDGAR | MRVI 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-02-25 | +13.8% | news | Business Wire | Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-25 | +13.8% | earnings | Seeking Alpha | Maravai LifeSciences Holdings GAAP EPS of -$0.24 misses by $0.13, revenue of $49.9M beats by $0.84M |
| 2026-02-25 | +13.8% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2026-02-25 | +13.8% | news | Business Wire | Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire |
| 2026-02-25 | +13.8% | earnings | Yahoo Finance | Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance |
| 2026-04-14 | +12.4% | news | Insider Monkey | Maravai LifeSciences (MRVI) Carrying Moderately Bullish Sentiment Despite Options-Linked Volatility |
| 2025-11-10 | +11.4% | news | Stock Titan | Maravai (NASDAQ: MRVI) at Stifel, Jefferies Conferences Nov 12 & 19; webcasts available - Stock Titan |
| 2025-01-28 | -10.7% | M&A | Seeking Alpha | Maravai LifeSciences acquires assets and intellectual property from Molecular Assemblies; shares rise |
| 2025-06-09 | -10.3% | executive | Seeking Alpha | Maravai LifeSciences appoints Bernd Brust as CEO |
| 2025-06-09 | -10.3% | legal | SEC EDGAR | MRVI 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-02-26 | +10.2% | earnings | Moby | Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary |
| 2026-02-26 | +10.2% | earnings | MarketBeat | Maravai LifeSciences Q4 Earnings Call Highlights |
| 2026-02-26 | +10.2% | earnings | Zacks | Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates |
| 2026-02-26 | +10.2% | earnings | Seeking Alpha | Maravai targets $200M–$210M 2026 revenue as restructuring drives early EBITDA turnaround |
| 2026-02-26 | +10.2% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript |
| 2026-02-26 | +10.2% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2022-05-05 | +10.2% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2024-05-08 | +9.5% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-03-31 | -9.4% | news | GlobeNewswire | Maravai LifeSciences Holdings, Inc. (MRVI) Admits to - GlobeNewswire |
| 2026-04-20 | +9.4% | earnings | Business Wire | Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026 |
| 2026-04-20 | +9.4% | earnings | Stock Titan | After the close May 7, Maravai posts Q1 results, webcast at 5 p.m. ET - Stock Titan |
| 2024-08-07 | -8.4% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-03-21 | -8.2% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2024 Earnings Conference Call Transcript |
| 2022-11-02 | -8.2% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-03-18 | -8.0% | legal | SEC EDGAR | MRVI 8-K: 2.02, 4.02 (SEC Filing) |
| 2025-05-13 | -7.4% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-05-13 | -7.4% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2025 Earnings Call Transcript |
| 2025-05-13 | -7.4% | earnings | Yahoo Finance | Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call Highlights: Navigating Growth ... - Yahoo Finance |
| 2025-11-15 | -7.3% | news | simplywall.st | Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Too Much Debt? - simplywall.st |
| 2024-12-05 | -6.8% | legal | SEC EDGAR | MRVI 8-K: 5.02 and 7.01 (SEC Filing) |
| 2025-10-27 | -6.7% | legal | SEC EDGAR | MRVI 8-K: 5.02 (SEC Filing) |
| 2023-02-22 | +6.5% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2022-01-20 | -6.4% | legal | SEC EDGAR | MRVI 8-K: 1.01 and (SEC Filing) |
| 2022-12-01 | -6.3% | legal | SEC EDGAR | MRVI 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-03-20 | -6.2% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2025-08-10 | -6.2% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Q2 2025 Earnings Preview |
| 2024-09-12 | -6.1% | legal | SEC EDGAR | MRVI 8-K: 1.01 and (SEC Filing) |
| 2021-08-10 | -6.1% | legal | SEC EDGAR | MRVI 8-K: 1.01, 2.02 (SEC Filing) |
| 2025-06-25 | +5.9% | executive | Seeking Alpha | Maravai Lifesciences appoints Rajesh Asarpota as chief financial officer |
| 2025-06-25 | +5.9% | legal | SEC EDGAR | MRVI 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-05-20 | +5.7% | expansion | Stock Titan | Revolutionary mRNA Synthesis Kit Achieves 2X Yield, 85% Lower dsRNA: TriLink's Game-Changing Launch - Stock Titan |
| 2025-03-17 | +5.6% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Q4 2024 Earnings Preview |
| 2025-11-07 | +5.6% | earnings | Seeking Alpha | Maravai anticipates $185M 2025 revenue and $10M–$20M annual COVID CleanCap sales as cost actions progress |
| 2025-11-07 | +5.6% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2025 Earnings Call Transcript |
| 2024-06-12 | -5.3% | legal | SEC EDGAR | MRVI 8-K: 5.02 (SEC Filing) |
| 2026-02-24 | +5.0% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Q4 2025 Earnings Preview |
| 2025-08-14 | -4.9% | earnings | simplywall.st | Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st |
| 2026-04-13 | +4.6% | earnings | Simply Wall St. | How Maravai LifeSciences (MRVI) Q4 Results Are Shaping A Cautious Valuation Narrative |
| 2026-04-13 | +4.6% | news | Yahoo Finance | Maravai LifeSciences (MRVI) Carrying Moderately Bullish Sentiment Despite Options-Linked Volatility - Yahoo Finance |
| 2026-04-13 | +4.6% | earnings | Yahoo Finance | How Maravai LifeSciences (MRVI) Q4 Results Are Shaping A Cautious Valuation Narrative - Yahoo Finance |
| 2026-04-13 | +4.6% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Maravai (MRVI) Stock Stronger Than Peers | Price at $3.06, Down 0.33% - High Beta Stocks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-16 | -4.6% | earnings | MarketBeat | Investors Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat |
| 2021-05-20 | -4.5% | legal | SEC EDGAR | MRVI 8-K: 5.02 and 5.07 (SEC Filing) |
| 2026-04-08 | +4.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Maravai (MRVI) Stock Priced Correctly | Price at $3.17, Up 9.86% - Stock Idea Sharing Hub - Cổng thông tin điện tử Tỉnh Sơn La |
| 2023-03-13 | +4.2% | legal | SEC EDGAR | MRVI 8-K: 5.02 (SEC Filing) |
| 2024-07-29 | +3.9% | legal | SEC EDGAR | MRVI 8-K: 5.02 and 7.01 (SEC Filing) |
| 2023-08-07 | -3.9% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2022-09-13 | +3.8% | analyst | TradingView | MRVI Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-05-11 | +3.8% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Q1 2025 Earnings Preview |
| 2025-08-13 | -3.7% | news | simplywall.st | 3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st |
| 2026-03-30 | -3.6% | analyst | Simply Wall St. | How The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value Targets |
| 2026-02-19 | +3.6% | news | Simply Wall St. | February 2026's Undervalued Small Caps With Insider Actions To Consider |
| 2024-12-18 | -3.4% | legal | SEC EDGAR | MRVI 8-K: 8.01 (SEC Filing) |
| 2023-07-27 | -3.2% | legal | SEC EDGAR | MRVI 8-K: 5.02, 7.01 (SEC Filing) |
| 2021-05-10 | -3.0% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-06-29 | -2.9% | news | Yahoo Finance | Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition - Yahoo Finance |
| 2026-04-06 | -2.6% | earnings | MarketBeat | Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Rating of "Hold" from Brokerages - MarketBeat |
| 2021-11-10 | +2.4% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2022-08-04 | +2.4% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-12-05 | -2.3% | news | simplywall.st | Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors - simplywall.st |
| 2026-03-17 | -2.0% | news | Stock Titan | Maravai (MRVI) General Counsel has 39,976 shares withheld for taxes - Stock Titan |
| 2026-03-17 | -2.0% | news | Stock Titan | [Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity - Stock Titan |
| 2026-02-27 | +1.8% | news | simplywall.st | Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives - simplywall.st |
| 2025-10-02 | -1.7% | legal | GlobeNewswire | MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, - GlobeNewswire |
| 2026-01-06 | +1.6% | news | simplywall.st | A US$75m Market Cap Boost Pleasing ToMaravai LifeSciences Holdings Insiders - simplywall.st |
| 2025-04-02 | +1.5% | news | Intellectia AI | MRVI Forecast — Price Prediction for 2026. Should I Buy MRVI? - Intellectia AI |
| 2025-11-05 | +1.4% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Q3 2025 Earnings Preview |
| 2025-02-26 | -1.3% | news | Seeking Alpha | Maravai cut to Neutral at Baird on reporting delays |
| 2022-02-23 | -1.3% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2026-01-29 | -1.3% | news | simplywall.st | Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90% - simplywall.st |
| 2026-02-16 | -1.2% | news | Simply Wall St. | Is There An Opportunity With Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 34% Undervaluation? |
| 2026-03-29 | +1.0% | analyst | Yahoo Finance | How The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value Targets - Yahoo Finance |
| 2025-11-06 | +1.0% | earnings | Seeking Alpha | Maravai LifeSciences Holdings, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-11-06 | +1.0% | earnings | Seeking Alpha | Maravai LifeSciences Holdings Non-GAAP EPS of -$0.08 in-line, revenue of $41.6M misses by $7.42M |
| 2025-11-06 | +1.0% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2025-11-06 | +1.0% | earnings | Yahoo Finance | Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance |
| 2025-02-27 | -0.9% | M&A | Yahoo Finance | Maravai LifeSciences Holdings, Inc. (MRVI) Acquires Officinae Bio to Enhance AI-Driven mRNA Development - Yahoo Finance |
| 2025-04-04 | +0.8% | news | Seeking Alpha | Maravai LifeSciences: Upside Not Likely In 2025, But Company Can Survive |
| 2025-04-04 | +0.8% | news | Seeking Alpha | Maravai LifeSciences: Upside Not Likely In 2025, But Company Can Survive (NASDAQ:MRVI) - Seeking Alpha |
| 2024-05-11 | +0.7% | earnings | MarketBeat | Maravai LifeSciences (MRVI) Stock Forecast and Price Target 2026 - MarketBeat |
| 2024-03-26 | +0.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-05-01 | +0.3% | earnings | Stock Titan | Life Sciences Leader Maravai Sets Q1 2025 Earnings Report Date - Key Details for Investors - Stock Titan |
| 2023-07-20 | +0.3% | legal | SEC EDGAR | MRVI 8-K: 5.02 and 7.01 (SEC Filing) |
| 2021-09-03 | -0.2% | legal | SEC EDGAR | MRVI 8-K: 1.01, 2.01 (SEC Filing) |
| 2025-09-28 | +0.1% | news | Seeking Alpha | Goldman's 48 potential M&A candidates |
| 2025-05-12 | +0.1% | earnings | Seeking Alpha | Maravai LifeSciences Holdings GAAP EPS of -$0.21 misses by $0.05, revenue of $46.9M beats by $2.89M |
| 2025-05-12 | +0.1% | legal | SEC EDGAR | MRVI 8-K: 2.02 and (SEC Filing) |
| 2026-04-24 | — | news | Stock Titan | Maravai (MRVI) sets 2026 virtual meeting, board elections and say-on-pay - Stock Titan |